Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Out-licenses Ex-China Rights for Two Immunotherapies in $1.3 Billion Agreement

publication date: Oct 27, 2020

CStone Pharma out-licensed global rights (ex-China) for two immunoncology assets to US-based EQRx in a $1.3 billion agreement. EQRx will own rights to sugemalimab, an anti-PD-L1, and CS1003, an anti-PD-1. CStone will receive $150 million upfront and up to $1.15 billion in milestone payments, plus royalties. EQRx was formed with the goal of bringing novel drugs to global markets at lower prices than the competition. In September, CStone sold China commercialization rights for sugemalimab to Pfizer in a $480 million deal. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.